HomeCompareCDXC vs PLD

CDXC vs PLD: Dividend Comparison 2026

CDXC yields 25.41% · PLD yields 3.18%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PLD wins by $6.40M in total portfolio value· pulled ahead in Year 6
10 years
CDXC
CDXC
● Live price
25.41%
Share price
$7.87
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$101.2K
Annual income
$11,579.48
Full CDXC calculator →
PLD
PLD
● Live price
3.18%
Share price
$128.78
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$6.50M
Annual income
$5,256,436.18
Full PLD calculator →

Portfolio growth — CDXC vs PLD

📍 PLD pulled ahead of the other in Year 6

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCDXCPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CDXC + PLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CDXC pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CDXC
Annual income on $10K today (after 15% tax)
$2,160.10/yr
After 10yr DRIP, annual income (after tax)
$9,842.56/yr
PLD
Annual income on $10K today (after 15% tax)
$270.62/yr
After 10yr DRIP, annual income (after tax)
$4,467,970.75/yr
At 15% tax rate, PLD beats the other by $4,458,128.19/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CDXC + PLD for your $10,000?

CDXC: 50%PLD: 50%
100% PLD50/50100% CDXC
Portfolio after 10yr
$3.30M
Annual income
$2,634,007.83/yr
Blended yield
79.75%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

CDXC
Analyst Ratings
6
Buy
2
Hold
Consensus: Buy
Altman Z
11.8
Piotroski
5/9
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+5.6% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CDXC buys
0
PLD buys
0
No recent congressional trades found for CDXC or PLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCDXCPLD
Forward yield25.41%3.18%
Annual dividend / share$2.00$4.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%74.4%
Portfolio after 10y$101.2K$6.50M
Annual income after 10y$11,579.48$5,256,436.18
Total dividends collected$64.5K$6.37M
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyBuy

Year-by-year: CDXC vs PLD ($10,000, DRIP)

YearCDXC PortfolioCDXC Income/yrPLD PortfolioPLD Income/yrGap
1$13,241$2,541.30$11,255$555.24+$2.0KCDXC
2$17,313$3,144.86$13,062$1,018.59+$4.3KCDXC
3$22,368$3,842.92$15,903$1,926.67+$6.5KCDXC
4$28,574$4,640.12$20,839$3,823.32+$7.7KCDXC
5$36,114$5,539.72$30,464$8,166.08+$5.7KCDXC
6← crossover$45,185$6,543.46$52,054$19,457.30$6.9KPLD
7$56,000$7,651.51$109,886$54,188.93$53.9KPLD
8$68,782$8,862.44$304,030$186,451.18$235.2KPLD
9$83,770$10,173.24$1,166,125$840,813.32$1.08MPLD
10$101,213$11,579.48$6,504,190$5,256,436.18$6.40MPLD

CDXC vs PLD: Complete Analysis 2026

CDXCStock

ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers, as well as to distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and IMMULINA, a Braun-type lipoproteins, including spirulina extracts and active compounds, which are used to support human immune function. It also offers analytical reference standards and services comprising supply of products to conduct quality control of raw materials and consumer products in dietary supplements, cosmetics, food and beverages, life sciences, and pharmaceutical industries. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation is headquartered in Los Angeles, California.

Full CDXC Calculator →

PLDREIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this CDXC vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CDXC vs SCHDCDXC vs JEPICDXC vs OCDXC vs KOCDXC vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.